Fractyl Health will present commercial strategy for Revita, a procedural intervention designed to sustain weight loss after GLP-1 therapy cessation. One-year midpoint data from REMAIN-1 showed treated participants maintained 84% of GLP-1-induced weight loss versus 46% in sham control, positioning the device as a potential bridge for the estimated 30 million U.S. adults currently on GLP-1 medications.
Key Points
- 84% weight loss maintenance one year post-Revita versus 46% sham control
- Designed as procedural alternative for GLP-1 therapy discontinuation
- FDA Breakthrough Device designation; De Novo application anticipated Q4 2026
Longevity Analysis
The persistence of weight loss after GLP-1 cessation remains a central clinical problem—most patients regain significant weight when medications stop. Revita's data suggests a mechanical intervention can sustain metabolic benefit achieved pharmacologically, which has implications for long-term metabolic health and the reduction of weight-related burden on cardiorespiratory and endocrine function. If efficacy holds in the pivotal cohort, this represents a meaningful shift in how sustained weight management could be approached—not through continuous pharmacotherapy, but through a one-time procedural intervention that appears to recalibrate energy balance independent of ongoing medication.
Original published by Longevity.Technology.